Cerrahi Tedavi Uygulanan Glioblastomlu Hastalarda Prognostik Faktörler ve Peritümöral Ödemin Sağ Kalım Üzerine Etkisi

Amaç: Cerrahi rezeksiyon sonrasında radyoterapi ve eş zamanlı kemoterapi uygulanan glioblastomlu hastaların genel özellikleri, sağ kalım süreleri, buna etki eden faktörleri ve peritümöral ödemin sağ kalıma etkisi geriye doğru incelenerek sonuçlar literatürle karşılaştırılmıştır. Gereç ve Yöntemler: Bu çalışmada Mayıs 2014-Kasım 2020 tarihleri arasında cerrahi rezeksiyon uygulanan ve histopatolojik tanısı WHO klasifikasyonuna göre glioblastom olan 69 hasta dahil edilmiştir. Çalışmaya 18 yaş üzerinde, takip süresi 2 aydan uzun olan ve radyoterapi ile eş zamanlı temozolomid tedavisi uygulanan hastalar dahil edilmiştir. Bilateral özellik gösteren, beyin sapı, talamus, infratentorial yerleşimli kitlesi olan hastalar ve sadece biyopsi yapılan hastalar dahil edilmemiştir. Bulgular: Yaş (p=0,015) ve rezeksiyon miktarının (p=0,044) glioblastomlu hastalarda prognostik faktör olduğu ortaya konulmuştur. Tanı anındaki peritümöral beyin ödemi, cinsiyet, kitlenin yerleştiği taraf ve tümör boyutu prognostik faktör olarak bulunmamıştır. Sonuç: Glioblastom tanılı hastalarda peritümöral beyin ödemi, kitlenin total olarak çıkarılmasını zorlaştırmaktadır. Fakat, PBÖ’nün glioblastom tanılı hastalarda prognostik bir faktör olmadığı belirlenmiştir.

Prognostic Factors and Effect of Peritumoral Edema on Survival in Patients with Glioblastoma underwent Resection

Aim: The general characteristics, survival periods, factors affecting survival and the effect of peritumoral brain edema on survival of patients with glioblastoma treated with radiotherapy and concurrent chemotherapy after surgical resection were examined retrospectively and the results were compared with the literature. Material and Methods: In this study, 69 patients who underwent surgical resection between May 2014 and November 2020 and whose histopathological diagnosis was glioblastoma according to the WHO classification were included. Patients over 18 years of age, with a follow-up period of more than 2 months and treated with radiotherapy simultaneously with temozolomide were included in the study. Patients with bilateral, brainstem, thalamus, infratentorial involvement and patients who only had biopsy were not included. Results: Age (p = 0.015) and amount of resection (p = 0.044) were found to be prognostic factors in patients with glioblastoma. Peritumoral brain edema at the time of diagnosis, gender, site of the mass and tumor size were not found as prognostic factors. Conclusion: Peritumoral edema makes total removal of the mass difficult in patients with a diagnosis of glioblastoma. However, it has been determined that peritumoral edema is not a prognostic factor.

PDF

___

1. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015. Neuro-oncology 2018;20(suppl_4):iv1-86.
2. Arvold ND, Reardon DA. Treatment options and outcomes for glioblastoma in the elderly patient. Clin Interv Aging 2014;9:357- 367.
3. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-766.
4. Helseth R, Helseth E, Johannesen T, Langberg C, Lote K, Rønning P, Scheie D, Vik A, Meling TR. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol Scand 2010;122(3):159-167.
5. Ryken TC, Frankel B, Julien T, Olson JJ. Surgical management of newly diagnosed glioblastoma in adults: Role of cytoreductive surgery. J Neurooncol 2008;89(3):271-286.
6. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-996.
7. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathol 2005;109(1):93-108.
8. Buckner JC. Factors influencing survival in high-grade gliomas. In Elsevier; 2003.10-4.
9. Carson KA, Grossman SA, Fisher JD, Shaw EG. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol 2007;25(18):2601-2006.
10. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 2001;95(2):190-8.
11. Stark AM, Nabavi A, Mehdorn HM, Blömer U. Glioblastoma multiforme-report of 267 cases treated at a single institution. Surgical Neurology 2005;63(2):162-169.
12. Stummer W. Extent of resection and survival in glioblastoma multiforme. Neurosurgery. 2009;64(6):E1206.
13. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE. 3. Lancet Oncol 2008;9(1):29-38.
14. Hill C, Hunter SB, Brat DJ. Genetic markers in glioblastoma: Prognostic significance and future therapeutic implications. Adv Anat Pathol 2003;10(4):212-217.
15. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu JI, Oka K, Ishimaru Y, Ushio Y. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63(20):6962-6970.
16. Schoenegger K, Oberndorfer S, Wuschitz B, Struhal W, Hainfellner J, Prayer D, Heinzl H, Lahrmann H, Marosi C, Grisold W. Peritumoral edema on MRI at initial diagnosis: An independent prognostic factor for glioblastoma? Eur J Neurol 2009;16(7):874-878.
17. Stummer W. Mechanisms of tumor-related brain edema. Neurosurgical Focus 2007;22(5):1-7.
18. Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neuro-Oncology 1996;27(1):65-73.
19. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. American Journal of Neuroradiology 2005;26(10):2466-2474.
20. Tortosa A, Viñolas N, Villà S, Verger E, Gil JM, Brell M, Caral L, Pujol T, Acebes JJ, Ribalta T, Ferrer I, Graus F. Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 2003;97(4):1063- 1071.
21. Xue D, Albright Jr RE. Preoperative anaplastic glioma tumor volume effects on patient survival. Journal Surgical Oncology 1999;72(4):199-205.
22. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. Lancet Oncol 2006;7(5):392-401.
23. Li YM, Suki D, Hess K, Sawaya R. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection? J Neurosurg 2016;124(4):977-988.
24. Han SJ, Sughrue ME. The rise and fall of “biopsy and radiate”: A history of surgical nihilism in glioma treatment. Neurosurg Clin N Am 2012;23(2):207-14, vii.
25. Rahman M, Abbatematteo J, De Leo EK, Kubilis PS, Vaziri S, Bova F, Sayour E, Mitchell D, Quinones-Hinojosa A. The effects of new or worsened postoperative neurological deficits on survival of patients with glioblastoma. J Neurosurg 2017;127(1):123-131.
26. Zhou X, Niu X, Mao Q, Liu Y. Clinical significance of various classification standards of age groups in predicting survival of patients with glioblastoma. Med Sci Monit 2020;26:e920627.
27. Gately L, Collins A, Murphy M, Dowling A. Age alone is not a predictor for survival in glioblastoma. Journal Neuro-Oncology 2016;129(3):479-485.
28. Mazurowski MA, Zhang J, Peters KB, Hobbs H. Computer- extracted MR imaging features are associated with survival in glioblastoma patients. Journal Neuro-Oncology 2014;120(3):483-488.
29. Gutman DA, Cooper LA, Hwang SN, Holder CA, Gao J, Aurora TD, Dunn Jr WD, Scarpace L, Mikkelsen T, Jain R, Wintermark M, Jilwan M, Raghavan P, Huang E, Clifford RJ, Mongkolwat P, Kleper V, Freymann J, Kirby J, Zinn PO, Moreno CS, Jaffe C, Colen R, Rubin DL, Saltz J, Flanders A, Brat DJ. MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology 2013;267(2):560-569.
30. Marcus HJ, Williams S, Hughes-Hallett A, Camp SJ, Nandi D, Thorne L. Predicting surgical outcome in patients with glioblastoma multiforme using pre-operative magnetic resonance imaging: development and preliminary validation of a grading system. Neurosurgical Review 2017;40(4):621-631.